Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of tirofiban sequential dual antiplatelet therapy in perforator atherosclerotic disease
ChiCTR2200062760Phase 4Not yet recruiting
- Sponsor
- Putian First Hospital
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of tirofiban in cerebral arteriosclerosis and branch atheromatous disease (BAD) (2 arms), sponsored by Putian First Hospital. Primary endpoint: Modified Rankin Scale score. Planned start Aug 2022; status: not yet recruiting.
02
Drugs
tirofiban
03
Conditions
cerebral arteriosclerosisbranch atheromatous disease (BAD)
Beyond the preview
Go deeper on ChiCTR2200062760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200062760.